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Abstract
Background
Ebola and Marburg viruses (family Filoviridae, genera Ebolavirus andMarburgvirus) cause
haemorrhagic fevers in humans, often associated with high mortality rates. The presence of
antibodies to Ebola virus (EBOV) and Marburg virus (MARV) has been reported in some Af-
rican countries in individuals without a history of haemorrhagic fever. In this study, we pres-
ent a MARV and EBOV seroprevalence study conducted amongst blood donors in the
Republic of Congo and the analysis of risk factors for contact with EBOV.
Methodology and Findings
In 2011, we conducted a MARV and EBOV seroprevalence study amongst 809 blood do-
nors recruited in rural (75; 9.3%) and urban (734; 90.7%) areas of the Republic of Congo.
Serum titres of IgG antibodies to MARV and EBOV were assessed by indirect double-immu-
nofluorescence microscopy. MARV seroprevalence was 0.5% (4 in 809) without any identi-
fied risk factors. Prevalence of IgG to EBOV was 2.5%, peaking at 4% in rural areas and in
Pointe Noire. Independent risk factors identified by multivariate analysis were contact with
bats and exposure to birds.
Conclusions/Significance
This MARV and EBOV serological survey performed in the Republic of Congo identifies a
probable role for environmental determinants of exposure to EBOV. It highlights the require-
ment for extending our understanding of the ecological and epidemiological risk of bats (pre-
viously identified as a potential ecological reservoir) and birds as vectors of EBOV to
humans, and characterising the protection potentially afforded by EBOV-specific antibodies
as detected in blood donors.
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Author Summary
Ebola and Marburg viruses cause haemorrhagic fevers often fatal to humans. Here, we
looked for antibodies to Ebola and Marburg viruses (i.e., markers of previous contact with
these viruses) in Congolese blood donors with no previous history of haemorrhagic fever.
We found serologic evidence for contact with Marburg and Ebola viruses in 0.5% and
2.5% of blood donors, respectively. The circulation of Marburg virus occurs at a very low
rate without any identified risk factor. In contrast, prevalence to Ebola virus was peaking
at 4% in rural areas and in Pointe Noire city. Importantly, we identified that contacts with
bats and birds constituted two independent environmental determinants of exposure. This
study confirms that contact with Ebola virus is not infrequent in Congo and can occur in
the absence of haemorrhagic fever. It highlights the requirement for further investigating
the role of bats and birds in the ecological cycle of Ebola, and for determining whether
asymptomatic contact with Ebola virus can provide subsequent protection against severe
forms of the Ebola disease.
Introduction
Marburg and Ebola viruses (family Filoviridae, generaMarburgvirus and Ebolavirus) cause se-
vere Viral Haemorrhagic Fever (VHF) in humans, with a high fatality rate in symptomatic
cases [1,2,3]. They appear to infect and persist in some species of fruit bats, that may serve as
natural reservoirs for these viruses [4,5,6,7,8,9]. Non-human primates have been a source of
human infections however they are not thought to be the reservoir as they develop severe, fatal
illness when infected [10].
The genusMarburgvirus currently consists of a single speciesMarburg marburgvirus, of
which the recognised members areMarburg virus (MARV) and Ravn virus [11,12]. The first
cases of Marburg haemorrhagic fever (MHF) occurred in Germany and Serbia (in the former
Yugoslavia) in 1967 and were linked to laboratory work using tissues dissected from African
green monkeys imported from Uganda [13,14]. The first major outbreak of MHF occurred in
Democratic Republic of the Congo (DRC, formerly Zaire), from 1998 to 2000 [15,16]. A sec-
ond, even more devastating outbreak occurred in Angola in 2004–2005 with a reported case fa-
tality rate (CFR) of almost 90% [17,18].
In Nigeria and DRC, seroprevalence studies identified antibodies to MARV in less than 2%
of apparently healthy people selected in general population in Nigeria and amongst healthcare
workers and general population in DRC [19,20]. In the Central African Republic (CAR), anti-
bodies to MARV were observed in both Pygmy (0.7–5.6%) and non-Pygmy (0.0–3.9%) popula-
tions [21]. An African serosurvey of VHF (Crimean-Congo haemorrhagic fever, Rift Valley
fever, Lassa, Hantaan, EBOV and MARV), conducted in the 1980s in the Central African gen-
eral population, reported low prevalence values: 0.3% in N’Djamena (Tchad), 2.6% in Bioco Is-
land (Equatorial Guinea) and, in the Republic of Congo, 3% in Pointe-Noire but no
seropositive sera to MARV detected in people in Brazzaville [22]. To date, no case of MHF has
been reported in the Republic of Congo.
The genus Ebolavirus includes five species: Zaire ebolavirus (Ebola virus: EBOV), Sudan ebo-
lavirus, Taï Forest ebolavirus, Reston ebolavirus and Bundibugyo ebolavirus [11,12]. The genus
Ebolavirus is primarily African in origin, with the exception of the species Reston ebolavirus
which is Asian [23]. EBOV was first identified in 1976, in Southern Sudan [24] and in the North
of DRC [25,26]. Since then, outbreaks have been described in several other African countries
(the Republic of Congo, Ivory Coast, DRC, Gabon, Sudan, Uganda, Guinea, Sierra Leone and
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Liberia) [1,27,28,29,30,31,32,33,34], with reported (CFR) frequently exceeding 50% amongst
symptomatic patients. In the Republic of Congo where the current study took place, several out-
breaks of (Zaire) EBOV were reported in the North of the country (2001 in Olloba-Mbomo,
2002 in Kéllé, 2003 in Mbandza-Mbomo), with 75 to 89% reported fatality rates [35,36,37].
In previous seroprevalence studies, amongst 1,517 apparently healthy persons tested in five
regions of the Cameroon, a positive rate of 9.7% was found with highest rates amongst Pygmies
(14.5%), young adults (11.6%) and rain forest farmers (13%) [38]. In CAR, the seropositivity
rate was 5.3% and Pygmies appeared to have a higher seroprevalence than non-Pygmies (7%
versus 4.2%) [21]. During the 1995 outbreak of Ebola virus disease in the region of Kikwit
(Democratic Republic of Congo), villagers had a greater chance of exposure (9.3%) than forest
and city workers (2.2%) [39]. In a large study conducted in 220 villages in Gabon (4,349 indi-
viduals enrolled), antibodies against EBOV were detected in 15.3% of those tested, with the
highest levels in forested regions (17.6% and 19.4% respectively in forest and deep forest areas),
suggesting the occurrence of mild or asymptomatic infections [40,41]. In the Republic of
Congo, seroprevalence values reported in the late 1980's were 7.8% in Pointe-Noire and 6.2%
in Brazzaville [22].
In Sierra Leone, in 2006–2008, among 253 febrile patients negative for Lassa fever and ma-
laria, antibodies against EBOV and MARV were detected in respectively 8.2% et 3.2% of the
samples [42].
In this study, we present an analysis of MARV and EBOV seroprevalence amongst blood
donors in the Republic of Congo in 2011 and we report associated risk factors for contact with
EBOV.
Materials and Methods
Study Design
AMARV and EBOV seroprevalence study was performed in 2011 in the Republic of Congo,
using a prospective cohort of blood donors.
Setting
Field samples for the study were collected fromMarch to July 2011, in the Republic of Congo
(Fig 1) in urban areas (Brazzaville and Pointe-Noire) and in rural locations (Gamboma,
Owando, Oyo and Ewo). Ewo is the capital of the Department of Cuvette-Ouest, where all pre-
vious EBOV outbreaks occurred.
This study was performed in collaboration with the Centre National de Transfusion San-
guine (CNTS) of Congo; the Virology Laboratory UMR_D 190 "Emergence des Pathologies
Virales" (Aix-Marseille University, IRD French Institute of Research for Development, EHESP
French School of Public Health), Marseille, France and the Virology Laboratory of Bernhard-
Nocht-Institut für Tropenmedizin, Hamburg, Germany.
Population Studied
Blood donors of both genders were included. The criteria for enrollment were eligibility for
blood donation and provision of informed consent without specific limiting factors. The age of
blood donors ranged from 18 to 65 years.
Ethical Considerations
Serum samples for serological analyses were collected in collaboration with the CNTS. In-
formed, written consent was obtained from each person enrolled in the study and the consent
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procedure was approved by the Congolese Research in Health Sciences Ethics Committee
(N° 00000065 DGRST/CERSSA).
Data Collection
A structured questionnaire was administered face-to-face, in the official language (French)
and/or in national languages (Lingala or Kutumba). All questionnaires were completed by the
medical personnel conducting the interviews.
The following data were collected: socio-demographic circumstances, domestic characteris-
tics (age, gender, occupation, residence, size of household, type of house, water resource, usage
of mosquito nets), environmental characteristics (animal contacts and/or consumption), travel
outside the country during their lifetime, history of haemorrhagic fever (in family or personal).
Fig 1. Map of Congolese study sites. Rural locations and Pointe-Noire city (circles); Brazzaville, the capital
(square). Brackets: number of positive samples/ total of samples.
doi:10.1371/journal.pntd.0003833.g001
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Serum
Venous blood samples were drawn using two 4 mL plain tubes which were immediately centri-
fuged. Sera were kept at -80°C until use. Aliquots were inactivated at 56°C for 30 min and
transferred to the Virology Laboratory of the Bernhard-Nocht-Institut (BNI) in Hamburg for
serological assays.
Serological Tests
Serum IgG antibodies specific for EBOV and MARV were titrated using indirect double-
immunofluorescence microscopy assays which were recorded as positive if reciprocal end
point titres were20 [43].
Antigens consisted of acetone-fixed Vero cells infected with Ebola virus (strain ATCC 1978)
or Marburg virus (strain Popp 1967). Cultivation of the viruses was carried out in an approved
and compliant BLS4 laboratory in BNI.
Serum samples were tested as serial twofold dilutions from 1:20 to 1:160 and antibodies
were detected with a Fluorescein isothiocyanate (FITC) labelled anti-human IgG antibody-
conjugate. Cell smears were counterstained with specific anti-Ebola or anti-Marburg nucleo-
capsid monoclonal antibodies (provided by the Institute of Virology, University of Marburg)
using a rhodamine-anti-mouse conjugate as secondary antibody [44]. As positive controls for
Ebola virus, we used (i) a human polyclonal antibody for the first IF with a titre at 2,560 (IgG)
and (ii) a mouse monoclonal antibody with a titre at 1,280 (IgG). As positive controls for Mar-
burg virus, we used (i) a human polyclonal antibody for the first IF with a titre at 1,280 (IgG)
and (ii) a mouse monoclonal antibody with a titre at 640 (IgG).
This “double immunofluorescence” protocol provides a much higher specificity than regu-
lar immunofluorescence assays, since only antibodies that detect filoviral antigens in co-locali-
sation with a monoclonal antibody are considered.
Statistical Analysis
Statistical analyses were performed using the IBM SPSS statistic 21 software. Analyses aiming
at analysing risk factors for seropositivity included univariate, stratified and multivariate analy-
ses. The Fisher’s exact test was used to compare proportions in univariate analysis and the
ANOVA test to compare means. The Pearson’s test was used for stratified analysis.
All statistical analyses were performed at the 95% confidence level. The association between
anti-EBOV IgG seropositivity and risk factors was determined by binary logistic regression
analysis. Stratified analysis based on sex, age and area were performed. The significant variables
in univariate analysis were entered in the multivariate model. The quality of the multivariate
model was assessed with Hosmer-Lemeshow’s test.
Results
Sociodemographic characteristics are presented in Table 1. Overall, 809 blood donors provided
serum samples; 734 (90.7%) lived in urban areas (62.9% and 27.8% in Brazzaville and Pointe-
Noire, respectively), 370 (45.7%) of which were younger than 30 years old (yo) with a median
age of 31. The gender ratio (Male/Female) was 3.02. Most blood donors lived in a modern
house 723 (89.4%). The two most common occupations were “student” (20.9%) and “unem-
ployed” (26.5%).
Epidemiological analyses of EBOV and MARV infections were performed separately. How-
ever, the same potential risk factors for seropositivity (gender, age, household size, occupation,
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mosquito net, travel risk, exposure to rodents/forests animals, and consumption of forests ani-
mals) were assessed for both viruses.
Individual titres of the MARV and EBOV-positives are presented in Table 2.
MARV-Specific IgG Seroprevalence
IgG to MARV was identified in 0.5% of the donors tested (4 in 809). Seropositivity could not be
significantly associated with any of the risk factors investigated in the individual questionnaire.
Antibodies to MARV were detected exclusively in male blood donors from Brazzaville who had
all been in contact (touching and catching) with rodents (mice and rats), but this is a common
feature in out cohort (>80% of the donors reported such contact). Three out of four were
Table 1. Socio-demographic characteristics of blood donors in study areas, March-July 2011.
Study population N = 809 General population N = 24,509
Residence; No. (%)
Brazzaville 509 (62.9) 11,962 (48.8)
Pointe-Noire 225 (27.8) 10,014 (40.9)
Rural areas 75 (9.3) 2,533 (10.3)
Gender
Male/Female 608/201 18,906/5,603
Gender ratio 3.02 3.37
Age, y
Mean 32.89 -
Median 31 -
Range 18–63 18–65
SD 10.21 -
Age groups; No. (%)
 29 y 370 (45.7) -
30–39 y 238 (29.4) -
40–49 y 130 (16.1) -
50+ y 71(8.8) -
Occupation; No. (%)
Health professional 88 (10.9) -
Ofﬁce worker 64 (7.9) -
Military 105 (13.0) -
Unemployed 214 (26.5) -
Student 169 (20.9) -
Hunter 17 (2.1) -
Cultivator 15 (1.9) -
Farmer 17 (2.1) -
Manual labourer 120 (14.8) -
Household size; No. (%)
1–5 439 (54.3) -
6–10 303 (37.5) -
 11 67 (8.3) -
Type of house; No. (%)
Modern 723 (89.4) -
Traditional 86 (10.6) -
doi:10.1371/journal.pntd.0003833.t001
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students (median age 23) and one (55yo) was an office worker. None had been in contact with
(or had eaten) forest animals or bats. The titre of IgG in positive donor ranged from 80 to 160.
EBOV-Specific IgG Seroprevalence
The overall prevalence of positivity for IgG when tested against EBOV was 2.5% (20 in 809). It
was 1.6% (8 in 509) in Brazzaville, 4% (3 in 75) in the rural locations (Gamboma, Owando,
Oyo and Ewo) and 4% (9 in 225) in Pointe-Noire.
Univariate Analysis
Table 3 summarises the association between potential risk factors and anti-EBOV IgG seropos-
itivity using univariate analysis. Amongst the populations studied there was no statistically sig-
nificant relationship between gender (p = 0.79), age (p = 0.96), travel (p = 0.62), household size
(p = 0.39), exposure to rodents (p = 0.63) and the presence of IgG to EBOV. However, being a
hunter (p = 0.01) was a risk factor, whereas the other occupations showed no statistical signifi-
cance in univariate analysis. The use of simple mosquito nets had a protective effect. Impor-
tantly, significant association with bat contact or eating birds (p values respectively of<0.001
and 0.01) was identified.
Table 2. Individual titres of the EBOV and MARV-positives.
Number of positive samples Sites IgG Titre
MARV
1 Brazzaville 80
2 Brazzaville 80
3 Brazzaville 160
4 Brazzaville 160
EBOV
1 Brazzaville >160
2 Brazzaville 80
3 Brazzaville 40
4 Brazzaville >160
5 Brazzaville >160
6 Brazzaville 160
7 Brazzaville 80
8 Brazzaville 80
9 Pointe-Noire 80
10 Pointe-Noire 80
11 Pointe-Noire 80
12 Pointe-Noire >160
13 Pointe-Noire 40
14 Pointe-Noire 20
15 Pointe-Noire 160
16 Pointe-Noire 40
17 Pointe-Noire 40
18 Gamboma 80
19 Ewo 40
20 Ewo 40
doi:10.1371/journal.pntd.0003833.t002
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Table 3. Association between potential risk factors and anti-EBOV IgG seropositivity.
Frequency; (%) Univariate analysis Multivariate analysis
Variables IgG + IgG - OR (95% CI) p-value OR (95% CI) p-value
Gender 0.41 0.63
Male 16 (2.6) 592 (97.4)
Female 4 (2.0) 197 (98.0)
Age groups 0.96 0.36
18–29 10 (2.7) 360 (97.3)
30–39 5 (2.1) 233 (97.9)
40–49 3 (2.3) 127 (97.7)
50+ 2 (2.8) 69 (97.2)
Household size 0.39
1–5 12 (2.7) 427 (97.3)
6–10 8 (2.6) 295 (97.4)
 11 0 67 (100.0)
Occupation
Health professional 0 88 (100) 0.09
Ofﬁce worker 2 (3.1) 62 (96.9) 0.47
Military 3 (2.8) 103 (97.2) 0.49
Unemployed 3 (1.4) 210 (98.6) 0.18
Student 6 (3.6) 163 (96.4) 0.22
Hunter 2 (11.8) 15 (88.2) 5.1 (1.3–20.6) 0.01 0.7
Cultivator 1 (6.7) 14 (93.3) 0.31
Farmer 0 17 (100) 0.65
Manual labourer 3 (2.5) 117 (97.5) 0.58
Type of house 0.64
Modern 18 (2.5) 705 (97.5)
Traditional 2 (2.3) 84 (97.7)
Mosquito net (usage)
Simple 3 (0.9) 338 (99.1) 0.24 (0.1–0.8) 0.01 0.06
Impregnated 9 (4.5) 190 (95.5) 0.06
Travels
Central Africa 7 (3.1) 219 (96.9) 0.31
West Africa 0 (0.0) 31 (100.0) 0.45
Other countries 0 (0.0) 31 (100.0) 0.45
Exposure to Rodents 0.58
Mice 17 (2.5) 669 (97.5) 0.638
Rats 9 (3.3) 260 (96.7) 0.18
Exposure to Forest animals
Bats 7 (14.0) 43 (86.0) 8.17 (3.4–19.6) <0.001 7.5 (2.6–21.7) <0.001
Monkeys 2 (8.0) 23 (92.0) 0.12
Birds 2 (4.1) 47 (95.9) 0.34
Antelopes 2 (8.3) 22 (91.7) 0.11
Snakes 1 (3.7) 26 (96.3) 0.49
Consumption of Forest Animals
Bats 0 (0.0) 23 (100.0) 0.55
Monkeys 12 (3.1) 380 (96.9) 0.20
Birds 10 (5.2) 182 (94.8) 3.21 (1.3–7.6) 0.01 2.6 (1.1–6.9) 0.04
Antelopes 12 (2.7) 436 (97.3) 0.42
Snakes 3 (2.0) 146 (98.0) 0.48
doi:10.1371/journal.pntd.0003833.t003
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Stratified Analysis
Seropositivity in age-groups was as follows: 2.7% in 18–29yo, 2.1% in 30–39yo, 2.3% in 40–
49yo, 3.2% in 50–59yo and 0.0% in>60yo, with no evidence for an increase of seroprevalence
with age. In the 18–29yo age-group, higher seroprevalence was associated with touching bats
(p<0.001). In the second group (30–39yo), higher seroprevalence was associated with the mili-
tary profession (p = 0.04). No significant association was found in the other age-groups. No sig-
nificant association was identified in a stratified analysis by occupation, including
military profession.
Regarding stratification by areas: in Pointe-Noire, to be a student (p = 0.002) or to have expo-
sure to bats (p<0.001) was statistically associated with anti-EBOV IgG. Exposure to bats
(p<0.001) was also found to be a risk factor in Brazzaville. Other variables (sex, age, household
size, type of house, travel risk, exposure to rodents, and consumption of forest animals) were not
significantly associated with the presence of IgG, regardless of the area in which donors lived.
Concerning stratification by gender (S1 Table), seropositivity was 2.6% in males and 2.0%
in females. No significant association was identified in females. Amongst the male subpopula-
tion, being a hunter (p = 0.009), having contact with bats (p<0.001) or monkeys (p = 0.01), or
consuming birds (p = 0.002) was statistically associated with EBOV IgG positivity. Other vari-
ables (age, household size, type of house, travel risk, exposure to rodents) had no statistically
significant relationship with the presence of IgG to EBOV.
Multivariate Analysis
In the multivariate model (Table 3), the only variables independently associated with Ebola an-
tibody detection were contact with bats (p<0.001) and bird consumption (p = 0.04).
Discussion
Whilst the Democratic Republic of the Congo and neighbouring Angola have experienced
Marburg disease outbreaks [2,45], no Marburg cases have been reported to date in the Re-
public of Congo. By contrast, human epidemics due to Ebola virus have been reported in the
Republic of Congo in 2001, 2002 and 2003. All outbreaks were located in the Cuvette-Ouest
Department [1,29,46].
Against this background, we conducted a seroprevalence study of Ebola and Marburg virus-
es amongst blood donors in the Republic of Congo, to estimate the seroprevalence of both vi-
ruses outside the epidemic period and also to identify possible risk factors. This study has some
obvious limitations related to the population studied (e.g., the number of blood donors origi-
nating from rural areas was small, all participants were older than 18 years old and 75% were
males) and to the capacity to collect epidemiological information without interfering with the
process of blood donation (for example, travel inside the country and activities outside the
main occupation were not documented). However a body of standardised information was ob-
tained from the questionnaires.
Importantly, our biological analyses identified antibodies specific for Ebola virus (and to a
lesser extent to Marburg virus) in healthy blood donors who did not report a history of haemor-
rhagic fever. This confirms previous studies suggesting that filoviruses can circulate in Africa in
the absence of severe clinical presentations (i.e., associated with asymptomatic or mild infections)
[47] and that Ebola virus-specific seroconversion can be observed without clinical manifestation
[21] or possibly associated with atypical clinical presentation. In the case of Ebola virus infec-
tions, asymptomatic seropositives have been identified by different techniques (e.g., immunofluo-
rescence [22] or ELISA [21]) and have been found more frequently in areas where Ebola cases
were reported [40]. In addition, Leroy and collaborators detected the Ebola virus genome in
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white blood cells of asymptomatic seroconverters investigated for up to 3 weeks following expo-
sure to documented Ebola symptomatic patients [41]. Contact with limited amounts of virus,
specific infection routes [48], specific characteristics of individual immunity leading to produc-
tion of specific IgG and early and strong inflammatory responses [47], may explain the presence
or absence of symptomatic presentation. Finally, a recent study identified asymptomatic seropo-
sitives with antibodies against various linear epitopes located in different and both structural and
non-structural EBOV proteins [49]. Altogether, this rules out the hypothesis that antibodies to
EBOV detected in asymptomatic individuals in previous studies are massively false positives.
It has been proposed that some populations may have been exposed to yet unidentified
virus strains that have relatively low pathogenicity for humans. Monath [50] proposed that
pathogenic strains may have independent transmission cycles involving species rarely in con-
tact with humans. In support of this hypothesis, Gonzalez [22] reported atypical serological re-
sponses in asymptomatic seropositives, consisting in identical titres against Ebola Mayinga
from Zaire and Ebola Boniface from Sudan identified in 89% of cases. This hypothesis still
stands but is weakened by (i) the fact that fifteen years of investigations of African wildlife spe-
cies have failed to identify such low pathogenicity strains in host species in close contact with
humans and (ii) the identification of asymptomatic seroconversions following contact with
symptomatic patients [41].
Monath [50] further proposed that pathogenic strains may emerge from non-pathogenic
strains by mutational events, but this hypothesis is weakened by the argument that the same
strain of EBOV has been shown to be responsible for symptomatic cases and secondary asymp-
tomatic cases [41].
In the late 1980's, Gonzalez and collaborators identified low MARV seroprevalence values
in Pointe Noire and Brazzaville (3 and 0%, respectively) [22]. In our study, the prevalence of
IgG to MARV was also low (0.5%) and could not be associated with specific risk factors. In
contrast, the prevalence of antibodies to EBOV was 2.5%, peaking at 4% in rural populations
and in the city of Pointe Noire. It was 1.6% in Brazzaville. Gonzalez and collaborators had pre-
viously reported 7.8 and 6.2% Ebola seroprevalence values in Pointe Noire and Brazzaville, re-
spectively [22]. The differences observed may be explained by different technical protocols
used for detection of antibodies, by the fact that studies were performed more than twenty
years apart, and by the investigation of different populations since Gonzalez studied randomly
selected clusters (providing representativeness of gender and age distribution). Against the lat-
ter hypothesis, it should be noted that, in both studies, no significant difference associated with
age-group and gender could be identified.
Nevertheless, two remarkable aspects of our epidemiological observations deserve further
discussion. On the one hand, antibodies to Ebola virus were detected in urban populations of
Congolese blood donors, which should stimulate future investigations relating to asymptomat-
ic seropositives. On the other hand, new environmental factors associated with seropositivity
have been identified. In neighbouring Gabon, the seroprevalence was significantly higher in
the forest regions (17.6%) than in savannah regions (10.5%) and Lakeland areas (2.7%) [40,48],
but no sociodemographic or behavioural risk factors associated with EBOV seropositivity
could be identified. Therefore, the finding in the current study that (i) exposure to bats and (ii)
bird consumption are associated independently in multivariate analysis with an increased prev-
alence of antibodies to EBOV is of particular relevance.
The notion of bird consumption must be interpreted with caution. If birds are consumed,
they will have been cooked, but bird consumption also implies contact with birds, either in the
markets in Africa or when capturing them or preparing them for cooking. Whilst further stud-
ies to clarify the role of birds as a possible source of human infection are clearly justified, we
prefer to refer to “exposure to birds” as a potential source of the detected seropositivity.
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The possibility of exposure to birds, with supporting evidence, has never been described be-
fore as a risk factor for filovirus infection. To the best of our knowledge, birds have not been as-
sociated with EBOV or virus antigen in previous investigations [51]. In 1979 and 1980, a total
of 1,664 animals (117 species, including 67 birds) were collected in the DRC and Cameroon
during the dry season near the site of the 1976 Ebola haemorrhagic fever epidemic. This study
failed to identify an animal reservoir of EBOV [52]. An ecologic investigation was also per-
formed to identify the reservoir of EBOV following the 1995 outbreak in Kikwit, DRC. Most of
the 3,066 collected specimens were mammals (87%, 2663), but birds (9%, 265) were also col-
lected. All attempts at isolation of EBOV remained negative [53]. During a study in CAR
(Ngotto forest) in 1998–99, 662 animals were trapped including 16 birds. Only Zaire ebolavirus
nucleotide sequences were detected in six organs rodents [54]. Finally, experimental inocula-
tion of birds with EBOV did not evidence significant acute or chronic replication [55].
In 1994, an outbreak of Ebola was described in a wild chimpanzee community in the Taï
National Park, Ivory Coast. Before the beginning of the outbreak, chimpanzees spent a long
time in a fig tree (Ficus goliath) that was full of fruits. Many birds (pigeons) were seen feeding
on the figs during the day, and rodents and fruit bats were feeding on the tree during the night.
It was proposed that the F. goliath could have constituted an epidemiological "hub", putting dif-
ferent species-including birds- in contact with one another [56].
The implication of birds in the epidemiology of filoviral disease was evoked by Monath [50]
in a hypothetical transmission cycle, taking into consideration the possibility that filoviruses
may be primary arthropod or plant viruses, transmitted to vertebrates including bats or other
insectivorous species such as birds. Jeffers et al. [57] reported in 2002 a noticeable biochemical
similarity between the glycoprotein of certain birds, oncogenic retroviruses and the EBOV gly-
coprotein. They suggested a possible common evolutionary origin which could be an indication
that avian species have or have had a role in the ecology and evolution of filoviruses. Accord-
ingly, the possible role of birds in the transmission of EBOV should not be ruled out and our
intriguing observation suggests that additional studies to elucidate the ecology of filoviruses in
birds would be of great interest.
The statistically significant identification of exposure to bats as an independent risk factor
for EBOV infection is also remarkable since contact with bats has been reported as a risk factor
for MARV infection [58,59,60,61], and fruit bats [6] (and possibly insectivorous bats [62]) are
thought to have a significant role in the ecological cycle of EBOV. Therefore, the current study
reinforces the suspected importance of bats in the natural cycle of Ebola virus and its possible
transmission to humans.
In Conclusion
Our results imply that in the Republic of Congo, the circulation of Marburg virus occurs at a
very low rate without any identified risk factor, but that human exposure to Ebola virus without
consequent disease is not infrequent. Living in Pointe Noire or in a rural area, and having con-
tact with bats and birds is associated with a higher risk of exposure to Ebola virus. Unfortunately,
little is known about the natural history and biological properties of EBOV antibody in individu-
als without haemorrhagic fever. Here, we did not observe an increase of seroprevalence with age,
which may suggest that, in some individuals, the antibody titre decreases and becomes undetect-
able with time. This would in turn imply the absence of iterative contacts with Ebola virus anti-
gens or that of a strong antibody response following such secondary antigenic exposure.
Similarly, the protection afforded by antibodies detected in blood donors against Ebola
virus infection remains completely unknown. How individuals without any history of haemor-
rhagic fever acquire specific antibodies to EBOV and what are the biological properties of such
Ebola and Marburg Viruses Seroprevalence in the Republic of Congo
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003833 June 5, 2015 11 / 15
antibodies (in particular what is their seroneutralising capacity) deserve further investigations
in African populations.
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